Ocular Therapeutix to Present New Phase 3 Data

Ocular Therapeutix shares were barely higher Monday morning after the biopharmaceutical firm said it will present new data from a phase 3 study evaluating the safety and efficacy of Dextensa for the treatment of ocular pain and inflammation following cataract surgery. The new data will be presented at the upcoming annual meeting of the American Society of Cataract and Refractive Surgery being held in Los Angeles from May 5-9.

Chief medical officer Jonathan Talamo said the company believes Dextenza “has the opportunity to offer an attractive alternative to the current post-operative standard of care for those recovering from ophthalmic surgery.”The company noted that the Food and Drug Administration set a Prescription Drug User Fee Act target action data of July 19 for the potential approval of Dextensa for treating ocular pain following ophthalmic surgery.

Leave A Reply

Your email address will not be published.